SSTR PET: Imaging Neuroendocrine Tumors

Authoring Organization

Publication Month/Year

February 1, 2023

Last Updated Month/Year

February 13, 2024

Supplemental Implementation Tools

Document Type


Country of Publication


Document Objectives

The goal of providing guidelines is to assist physicians in recommending, performing, interpreting and reporting the results of SSTR PET imaging studies for patients with NETs. This document aims to provide clinicians with the best available evidence, to inform where robust evidence is lacking, and to help them to deliver the best possible diagnostic efficacy and study quality for their patients. This guideline also presents standardized quality control/quality assurance (QC/QA) procedures and imaging procedures for SSTR PET. Adequate precision, accuracy, repeatability, and reproducibility are essential for the clinical management of patients and the use of SSTR PET within multicenter trials. A standardized imaging procedure will help to promote the appropriate use of SSTR PET and enhance subsequent research.

Inclusion Criteria

Male, Female, Adult, Older adult

Health Care Settings

Outpatient, Radiology services

Intended Users

Nurse, nurse practitioner, physician, physician assistant


Diagnosis, Assessment and screening

Diseases/Conditions (MeSH)

D018278 - Carcinoma, Neuroendocrine, D049268 - Positron-Emission Tomography, D013004 - Somatostatin


positron emission tomography (PET), Neuroendocrine tumor, SSTR, Somatostatin receptor, PET, positron emission tomography, NETs

Source Citation

Hope TA, Allen-Auerbach M, Bodei L, Calais J, Dahlbom M, Dunnwald LK, Graham MM, Jacene HA, Heath CL, Mittra ES, Wright CL, Fendler WP, Herrmann K, Taïeb D, Kjaer A. SNMMI Procedure Standard/EANM Practice Guideline for SSTR PET: Imaging Neuroendocrine Tumors. J Nucl Med. 2023 Feb;64(2):204-210. doi: 10.2967/jnumed.122.264860. PMID: 36725249.